A Nutraceutical Rich in Docosahexaenoic Acid Improves Portal Hypertension in a Preclinical Model of Advanced Chronic Liver Disease
Zoe Boyer‐Díaz, Jordi Gracia‐Sancho(Institut d'Investigacions Biomèdiques de Barcelona), Estefanía de Gregorio(Institut d'Investigacions Biomèdiques de Barcelona), Begoña Cordobilla(Universitat de Barcelona), Laia Abad‐Jordà(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Martí Ortega‐Ribera(Beth Israel Deaconess Medical Center), Peio Aristu-Zabalza(Departament de Salut), Nicolò Manicardi(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Montserrat Marı́(Institut d'Investigacions Biomèdiques de Barcelona), Jaime Bosch(University Hospital of Bern), Joan Carles Domingo(Universitat de Barcelona), Anabel Fernández‐Iglesias(Hospital Clínic de Barcelona)
Cited by 22
Related Papers
Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease
|Journal of Hepatology|2020|163
Cysteine cathepsins control hepatic NF-κB-dependent inflammation via sirtuin-1 regulation
|Cell Death and Disease|2016|74
A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target
|Cellular and Molecular Gastroenterology and Hepatology|2019|60